Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
10.52 USD +9.93% Intraday chart for CareDx, Inc +4.99% -12.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors CI
Transcript : CareDx, Inc, Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (CDNA) CAREDX Reports Q4 Revenue $65.6M, vs. Street Est of $64.1M MT
CareDx, Inc Provides Revenue Guidance for the Full Year of 2024 CI
CareDx, Inc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
CareDx, Inc Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring CI
Natera Awarded About $96.3 Million in Patent Infringement Case Against CareDx MT
Transcript : CareDx, Inc - Special Call
CareDx's Preliminary Q4, 2023 Revenue Top Consensus MT
Tranche Update on CareDx, Inc's Equity Buyback Plan announced on December 6, 2022. CI
CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023 CI
CareDx, Inc Revises Revenue Guidance for the Full Year Ended December 31, 2023 CI
Natera Says Delaware Court Denies CareDx's Motion for Summary Judgment on Two Patents, Lawsuit to Proceed to Trial MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care MT
Natera Says Delaware Court Denies CareDx's Motion for Summary Judgment on Two Patents, Lawsuit to Proceed to Trial MT
Transcript : CareDx, Inc - Special Call
North American Morning Briefing : Investors Weigh -2- DJ
Stephens Upgrades CareDx to Overweight From Equalweight, Price Target is $10 MT
Wall Street Set to Open Higher Thursday as Jobless Claims Fall, Ahead of Powell Speech MT
CareDx Surges 14% Premarket Thursday After Reporting Q3 Revenue Above Expectations, Lifting Full-Year Sales Guidance MT
Transcript : CareDx, Inc, Q3 2023 Earnings Call, Nov 08, 2023
Tranche Update on CareDx, Inc's Equity Buyback Plan announced on December 6, 2022. CI
CareDx, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (CDNA) CAREDX Reports Q3 Revenue $67.2M, vs. Street Est of $53.1M MT
Chart CareDx, Inc
More charts
CareDx, Inc. is a precision medicine company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its suite of AlloSeq products includes AlloSeq Tx, AlloSeq cfDNA, AlloSeq HCT, TruSight HLA, Olerup SSP and QTYPE. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
10.52 USD
Average target price
12.4 USD
Spread / Average Target
+17.87%
Consensus
  1. Stock
  2. Equities
  3. Stock CareDx, Inc - Nasdaq
  4. News CareDx, Inc
  5. Earnings Flash (CDNA) CAREDX Posts Q1 Loss $-0.13, vs. Street Est of $-0.04